1-53211181-C-T
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM2PP3_StrongPP5_Very_Strong
The NM_000098.3(CPT2):c.1507C>T(p.Arg503Cys) variant causes a missense change. The variant allele was found at a frequency of 0.0000131 in 1,608,362 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R503H) has been classified as Uncertain significance.
Frequency
Consequence
NM_000098.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CPT2 | NM_000098.3 | c.1507C>T | p.Arg503Cys | missense_variant | 4/5 | ENST00000371486.4 | NP_000089.1 | |
CPT2 | NM_001330589.2 | c.1507C>T | p.Arg503Cys | missense_variant | 4/5 | NP_001317518.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CPT2 | ENST00000371486.4 | c.1507C>T | p.Arg503Cys | missense_variant | 4/5 | 1 | NM_000098.3 | ENSP00000360541.3 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152182Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000405 AC: 1AN: 247112Hom.: 0 AF XY: 0.00000749 AC XY: 1AN XY: 133538
GnomAD4 exome AF: 0.0000130 AC: 19AN: 1456180Hom.: 0 Cov.: 34 AF XY: 0.0000124 AC XY: 9AN XY: 723500
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152182Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74342
ClinVar
Submissions by phenotype
Carnitine palmitoyltransferase II deficiency Pathogenic:3Other:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 25, 2023 | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 503 of the CPT2 protein (p.Arg503Cys). This variant is present in population databases (rs74315296, gnomAD 0.003%). This missense change has been observed in individual(s) with CPT2-related conditions (PMID: 10090476, 10873395, 17372854, 19762733, 21913903; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 8959). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CPT2 protein function with a positive predictive value of 80%. This variant disrupts the p.Arg503 amino acid residue in CPT2. Other variant(s) that disrupt this residue have been determined to be pathogenic (Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Feb 16, 2024 | Variant summary: CPT2 c.1507C>T (p.Arg503Cys) results in a non-conservative amino acid change located in the choline/carnitine acyltransferase domain (IPR039551) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4e-06 in 247112 control chromosomes (gnomAD). c.1507C>T has been reported in the literature as a biallelic genotype in at least two individuals affected with Carnitine Palmitoyltransferase II Deficiency and in several other affected individuals in whom no second variant was identified, but who had CPT activity below the normal range (e.g. Taggart_1999, Thuiller_2003, Spiegel_2007, Hogan_2009, Fanin_2012, ). These data indicate that the variant is likely associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 21913903, 19762733, 17372854, 10090476, 12673791, 10873395). ClinVar contains an entry for this variant (Variation ID: 8959). Based on the evidence outlined above, the variant was classified as likely pathogenic. - |
not provided, no classification provided | literature only | GeneReviews | - | - - |
Likely pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Nov 25, 2020 | - - |
Carnitine palmitoyl transferase II deficiency, myopathic form;C1833511:Carnitine palmitoyl transferase II deficiency, severe infantile form;C1833518:Carnitine palmitoyl transferase II deficiency, neonatal form;C3280160:Encephalopathy, acute, infection-induced, susceptibility to, 4 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Dec 02, 2021 | - - |
Carnitine palmitoyl transferase II deficiency, myopathic form Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Jun 01, 2000 | - - |
Encephalopathy, acute, infection-induced, susceptibility to, 4 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Jan 06, 2024 | - - |
Carnitine palmitoyl transferase II deficiency, severe infantile form Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Apr 11, 2023 | - - |
not provided Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jan 25, 2023 | Reported as heterozygous in several unrelated individuals with myopathic symptoms with reduced CPT2 activity in fibroblasts; a second variant in CPT2 was not identified in these individuals (Taggart RT et al., 1999; Vladutiu GD et al., 2000; Fanin et al., 2012).; Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 22975760, 17372854, 18550408, 12673791, 14615409, 10090476, 16996287, 21913903, 19762733, 34426522, 35641460, 25929793, 10873395, 32295037) - |
Carnitine palmitoyl transferase II deficiency, severe infantile form;C1833518:Carnitine palmitoyl transferase II deficiency, neonatal form Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | - | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at